ABS-201 / Absci Corp - LARVOL DELTA

Prolactin Receptor Antagonism by ABS-201 Drives Hair Follicle Growth and Stem/Progenitor Cell Expansion in Human Male Scalp Skin (EADV 2026) - No abstract available

Absci…reported interim Phase 1 data from the HEADLINE trial for ABS-201, which reported positive results on safety and pharmacokinetics - "The trial began dosing its first participants in December 2025, and Absci expects further clinical readouts over the next two years."

P1 data • Alopecia • Immunology

ABS-101 (anti-TL1A antibody) (GlobeNewswire) - "Interim data for the Phase 1 clinical trial for ABS-101 demonstrated extended half-life as compared to first-generation anti-TL1A competitor programs, with no apparent impact of ADA on PK, with the overall safety profile being favorable with no serious adverse events reported. With this data, Absci will explore potential partnership and outlicensing opportunities for ABS-101, consistent with the company's business strategy, as well as first-in-class indication expansion opportunities for this target. The company has made the strategic decision not to initiate additional later-stage development trials for ABS-101 internally at this time. Instead, Absci will allocate capital and resources toward expanded and accelerated clinical development of ABS-201 in endometriosis, where there is a high unmet medical need and market opportunity."

Clinical • P1 data • Immunology • Inflammatory Bowel Disease